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We retrospectively analyzed the outcomes of 26 patients
with acute promyelocytic leukemia (APL) in the first CR
(CR1) or second CR (CR2), who underwent autologous
PBSCT (auto-PBSCT) between 1992 and 2008. All
patients received all-trans retinoic acid-based induction
therapy. After two courses of consolidation chemotherapy,
upfront auto-PBSCT was performed in 20 patients in the
CR1. Five patients had a high WBC count of more than
10 109/L (high risk), while 15 patients had a count of
less than 10 109/L (low risk) at initial presentation. In
addition, six patients, who were considered as low-risk
patients at presentation, had a relapse after three cycles of
consolidation and 2 years of maintenance therapy, but
gained the molecular remission after re-induction and
consolidation, and underwent auto-PBSCT in the CR2. In
26 recipients, engraftment was rapid and no TRM was
documented. All 20 patients autotransplanted in CR1 were
still in CR at a median of 133 months (73–193 months),
and six patients who underwent auto-PBSCT in CR2 were
also still in CR at a median of 41 months (2–187 months)
without maintenance therapy. PML/RARa chimeric
mRNA was undetectable in PBSC or BM samples
examined before auto-PBSCT. Despite a small number
of cases studied, our retrospective observations suggest
that auto-PBSCT may be an effective treatment option
to continue durable CR in the treatment of high-risk
APL. We review previous reports and discuss the role
of autotransplantation in the treatment of APL patients
in CR.
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Introduction
Combination therapy with upfront all-trans retinoic acid
(ATRA) and anthracycline-based chemotherapy for induc-
tion and consolidation, as well as ATRA-based mainte-
nance, has dramatically improved the outcomes of patients
with acute promyelocytic leukemia (APL).1,2 This treat-
ment strategy is currently the standard of care for newly
diagnosed APL patients. However, relapse occurs in about
20% of patients receiving ATRA and chemotherapy, and is
still a major obstacle to cure for APL patients.3–6 A recent
multivariate analysis revealed that APL patients with a
WBC count of more than 10 109/L at initial presentation
have a significantly increased relapse risk and poorer
survival.1,3,7 New strategies include risk-adapted therapies
to intensify the use of anthracyclines and/or cytarabine
(CA) in either induction or consolidation of high-risk APL
patients.1,8,9
Autologous hematopoietic SCT (HSCT) has been widely
used to consolidate remission in patients with acute
myelogenous leukemia.10,11 As new risk-adapted treatment
strategies combined with upfront ATRA have provided
higher cure rates, HSCT might not always be necessary for
APL patients who are in the first complete molecular
remission at the end of consolidation.12 Therefore, the role
of HSCT in the front-line APL therapy has changed during
recent years. In this paper, we use historical data to
report the long-term safety and therapeutic efficacy of
myeloablative therapy followed by autologous PBSCT
(auto-PBSCT) in 20 APL patients in the first CR (CR1)
and six patients in the second CR (CR2). We discuss the
role of auto-HSCT for APL patients based on our
observations and previously reported literature.
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Materials and methods
Patient characteristics
Between April 1992 and November 2008, 26 APL patients,
who were treated with myeloablative conditioning followed
by auto-PBSCT in remission, were enrolled in this study at
seven institutions of the Fukuoka Blood & Marrow
Transplant Group (FBMTG). All patients were diagnosed
as APL morphologically according to the FAB classifica-
tion. The diagnosis was also confirmed by the presence of
t(15; 17)(q22; q21) by karyotypic analysis and/or detection
of the PML/RARa transcript by reverse transcription PCR
(RT-PCR).
Clinical characteristics of these patients are listed in
Table 1. The patients comprised 14 males and 12 females
with a median age of 45 years (16–68 years). Of these 26
patients, 20 received upfront auto-PBSCT in CR1 between
April 1992 and November 2002. Five of these 20 patients
had a WBC count of more than 10 109/L and were
considered as high-risk patinets,1,3,7 and six patients
showed additional karyotypic abnormalities with t(15;17)
at presentation (Table 1). In contrast, after August 1993,
according to the policy of each institution, APL patients in
molecular CR1 after consolidation are no longer always
indicated for upfront auto-PBSCT. Consequently, six
patients received auto-PBSCT in CR2 during the period
up to November 2008, although all of these six patients had
a WBC count of less than 10 109/L at presentation, but
had a relapse of APL after cessation of maintenance
therapy for CR1. This study was conducted in accordance
with the ethical guidelines of the Declaration of Helsinki.
Chemotherapy and collection of PBSCs
Remission induction therapy for 23 patients consisted of
ATRA 45mg/m2 orally and anthracyclines including DNR
or idarubicin intravenously (i.v.). The remaining three
patients were treated with ATRA alone at the same dosage
because their WBC count at presentation was less than
0.5 109/L. Consolidation chemotherapy consisted of
cytosine arabinocide (CA) 500mg/m2 i.v. every 12 h for 6
days (intermediate-dose CA) combined with mitoxantrone
7mg/m2 i.v. for 3 days in the first course and etoposide
100mg/m2 i.v. for 5 days in the second course.10,13
In 20 patients who were assigned to receive upfront auto-
PBSCT in CR1, auto-PBSCs were collected during the
hematopoietic recovery phase after the second course of
consolidation followed by G-CSF (filgrastim; Kyowa
Hakko Kirin, Japan). Collected and unmanipulated PBSCs
were cryopreserved until transplantation. The remaining six
patients after the second consolidation chemotherapy were
treated with an additional course of intermediate-dose CA
combined with DNR 25mg/m2 for 4 days, followed by
treatment with ATRA, and low-dose MTX and mercapto-
purine as maintenance therapy as described by Sanz et al.1
Thereafter, these six patients, who had a WBC count of less
than 10 109/L at presentation and were considered as
low-risk patients, had a relapse of leukemia at a median of
22 months (8–54 months) after diagnosis. Three patients
showed molecular relapse, which was detected by RT-PCR,
whereas the remaining three patients showed hematologic
relapse. Three patients received re-induction cytotoxic
chemotherapy without arsenic trioxide (ATO), and the
remaining three patients received ATO 0.15mg/m2 with or
without idarubicin. All six patients achieved molecular
CR2 after one course of re-induction chemotherapy. Auto-
PBSCs were collected after an additional two or three
course of consolidation chemotherapy in these patients.
Auto-PBSCT
The pretransplant conditioning regimen for all patients
consisted of BU 1mg/kg every 6 h orally on days 8 to 5,
etoposide 20mg/kg i.v. on days 4 and 3 and CA 3g/m2
i.v. every 12 h on days 3 and 2 (BEA regimen).10,13
Concurrently, G-CSF was administered to prime residual
leukemic cells at a dose of 5mg/kg on days 14 to 6,
10 mg/kg on days 5 to 4 in combination with continuous
infusion of CA 100mg/m2 i.v. on days 12 to 6.
Cryopreserved PBSCs were rapidly thawed in a 37 1C
water bath and infused on day 0.
RT-PCR analysis
Nested RT-PCR analysis of PML/RARa chimeric mRNA
was performed to detect minimal residual disease (MRD)
with sensitivity threshold between 106 and 107 in PBSC
samples in 15 of 20 patients who underwent auto-PBSCT
in CR1, and BM samples in all six patients just before auto-
PBSCT in CR2 as described previously.14
Results
Auto-PBSCT in CR1
Twenty patients received upfront high-dose chemotherapy
(G-SCF-combined BEA regimen) with auto-PBSCT during
CR1 after a median of 6 months (5–13 months) from the
initial diagnosis. A median dose of 7.1 106 CD34þ cells/
kg was transplanted. No engraftment failure was observed.
The median days to reach a granulocyte count above
0.5 109/L, a plt count above 20 109/L, and indepen-
dence from plt transfusion was 15 days (range, 13–24 days),
11 days (range, 8–210 days) and 11 days (range, 6–191
days), respectively. No treatment-related deaths were
observed after auto-PBSCT. Grades 1–2 stomatitis and
diarrhea occurred in most recipients; however, significant
adverse events, which were graded in accordance with
National Cancer Institute Common Toxicity Criteria
(version 2.0), above grade 3 were not observed.
At a median follow-up time of 133 months (73–193
months), all of 20 patients were continuing CR1 without
maintenance therapy. Nested RT-PCR analysis was per-
formed to test contamination of the infused PBSCs with
APL cells. PML/RARa chimeric mRNA was undetectable
in PBSCs samples obtained from all 15 patients. After auto-
PBSCT (median follow-up time, 43 months), MRD could
not be detected in BM samples from any of these patients
(Table 1).
Auto-PBSCT in CR2
Six patients, who had relapse but achieved CR2 after
re-induction chemotherapy, were assigned to receive
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auto-PBSCT. RT-PCR analyses of BM samples obtained
from all six patients before auto-PBSCT were negative for
MRD (Table 1). They received G-SCF-combined BEA
regimen followed by auto-PBSCT after a median of 26
months (12–61 months) from the initial diagnosis. A
median dose of 6.1 106 CD34þ cells/kg was transplanted.
Engraftment was documented in all six patients. The
median days to reach a granulocyte count above
0.5 109 /L, a plt count above 20 109 /L and indepen-
dence from plt transfusion was 11 days (range, 9–12 days),
14 days (range, 11–15 days) and 11 days (range, 8–15 days),
respectively. No treatment-related deaths and no significant
adverse events above grade 3 were documented. No
significant difference was observed in hematopoietic
recovery or adverse effect between 20 and 6 patients in
CR1 and CR2, respectively, after auto-PBSCT. All six
patients who received transplantation in CR2 remained in
CR at a median follow-up time of 41 months (2–187
months) without maintenance therapy.
Discussion
The European Cooperative Group for Blood and Marrow
Transplantation (EBMT) group conducted a survey on
APL patients who underwent HSCT between 1993 and
2003 in Europe.15 In their analysis of 625 APL patients, the
number of auto-HSCT has decreased progressively for
patients in CR1 since 1998, whereas that for patients in
CR2 has remained stable. The emergence of a new risk-
adapted treatment strategy combining ATRA and ATO
has dramatically changed the role of auto-HSCT in the
treatment of APL in CR1 and CR2. In contrast, allogeneic
HSCT should be considered for patients with persistent
MRD or without hematologic remission if an HLA-
matched donor is available.12
Auto-HSCT in CR1
Large multicenter studies have shown that treatment
regimens combining upfront ATRA and chemotherapy
have provided high cure rates.2–7 In addition, multivariate
analyses have revealed that the most important factor
predicting relapse is a WBC count of more than 10 109/L
at initial presentation.1,3,7 Therefore, many investigators
have tried to classify the risk for each patient and modulate
the regimen to intensify the use of anthracyclines and/or
CA in either induction or consolidation therapy for high-
risk patients.1,9 A joint analysis by the Spanish cooperative
group ‘Programa para el Estudio de la Terape´utica en
Hemopatı´a Maligna’ (PETHEMA) and the European
‘French-Belgian-Swiss APL’ group compared the outcomes
of PETHEMA LPA99 and European APL 2000 trials, and
demonstrated that addition of high-dose of CA in
consolidation has benefited high-risk patients.5 Thereafter,
through the combined analysis of APL93 and APL2000
trials, the European APL group confirmed a dramatically
improved outcome of APL patients with high WBC counts
when treated with escalating dose of CA in APL2000 trial:
between these two trials, CR rate increased from 89 to
93%, and the 5-year cumulative incidence of relapse
decreased from 40 to 9.5% in patients with high WBC
counts (between 10 to 50 109/L). In patients with very
high WBC counts of more than 50 109/L, the CR rate
increased from 82 to 91%, and 5-year cumulative incidence
of relapse decreased from 59 to 24%.9 These results showed
that upfront ATRA combined with intensified consolida-
tion with high-dose CA has potential benefits for high-risk
APL patients. Therefore, in terms of the intensification of
chemotherapy, theoretically auto-PBSCT would be the best
therapy to maximize the antileukemia effect and to
minimize TRM by rapid engraftment, especially for high-
risk patients, if TRM can be reduced as much as possible.
In our study, upfront auto-PBSCT was performed in 20
APL patients in CR1 after consolidation, which included 5
high-risk patients. Engraftment was rapid, and TRM was
not documented. All of these patients continued in CR for
more than 10 years without maintenance therapy, indicat-
ing that leukemia-free survival (LFS) at 10 years was 100%.
All infused PBSCs were negative for MRD in good-risk
and high-risk patients who were examined (Table 1). Thus,
high-dose chemotherapy followed by auto-PBSCT and
deep CR status, reflecting negative MRD in PBSCs, would
have benefited our patients, as several reports indicated
that molecular CR would be an important factor for
patients autotransplanted in CR2. In contrast, according to
the multicenter retrospective survey from the EBMT group,
LFS at 5 years was B70% in 149 APL patients in CR1
receiving auto-HSCT, indicating that the results in APL
patients autotransplanted in CR1 were not better than
those in patients given ATRA-combining risk-adapted
chemotherapy.5 In addition, a long-term follow-up study
with a median of 10 years of follow-up (APL 93 trial)
recently revealed the benefits of prolonged maintenance
with ATRA plus chemotherapy for high-risk patients with
initial WBC counts of more than 5 109/L.16 In these high-
risk patients, cumulative incidence of relapse declined from
68.4% with no maintenance to 20.6% with combined
ATRA and chemotherapy maintenance. On the basis of
Table 1 Patient characteristics
CR1 (n¼ 20) CR2 (n¼ 6)
Age 45 (16–68) 45.5 (37–50)
Sex (male/female) 12/8 2/4
WBC at diagnosis
410 109/L 5 0
p10 109/L 15 6
Additional chromosomal abnormality
Yes 6 1
No 14 5
Months from diagnosis to auto-PBSCT 6 (5–13) 25.5 (12–61)
Months from auto-PBSCT to present 133 (37–193) 41 (2–187)
Infused CD34+ cells ( 106cells/kg) 7.1 (1.03–20.2) 6.1 (0.5–11.2)
Minimal residual disease (PCR)
Pretransplant BM samples NE Negative 100%
(6 of 6)
Graft (PBSC) samples Negative 100%
(15 of 15)
NE
Abbreviations: auto-PBSCT¼ autologous PBSCT; CR1¼ first CR; CR2¼
second CR; NE¼not examined.
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these results, auto-HSCT is not routinely recommended for
APL patients in CR1,12,17 although there has been no
randomized trial to compare outcomes among APL
patients in CR1 receiving upfront auto-HSCT vs ATRA-
combining risk-adapted chemotherapy for induction,
consolidation and maintenance.15,18–21
Auto-HSCT in CR2
For APL patients who had relapse after ATRA-containing
regimens, ATO is presently considered as the best treatment
option; 2-year OS was reported to be approximately
between 50 and 60% after repeated cycles of ATO
combined with chemotherapy in relapsed APL patients
achieving CR2.22,23 The consolidation strategy after ATO-
induced CR2 generally consists of HSCT, and the choice of
transplant modality is mainly based on PCR status.
Allogeneic HSCT is restrictively chosen for patients failing
to achieve molecular CR2, as allogeneic HSCT offers
greater antileukemic activity because of its GVL effect, but
obviously involves a greater risk of TRM.23 Auto-HSCT
was recently considered to be one of the most useful
options for consolidation in relapsed APL patients.12,15,17,23
In a report of the EBMT group, 195 APL patients in
CR2 autotransplanted between 1993 and 2003 were
enrolled in the survey; the 5-year estimate of LFS was
51%.15 Although no data were available on re-induction
and consolidation chemotherapy, or on PCR status of the
graft and/or recipients before transplant, the results
demonstrated that a large population of patients in CR2
achieved long-term OS after auto-HSCT. De Botton et al.24
also discussed the benefit of auto-HSCT in 50 APL patients
who relapsed after ATRA-containing treatment in 2004.
The relapse-free survival at 7 years was 79.4% with a TRM
of 6% after auto-HSCT. They analyzed MRD status in 30
available cases. PCR before auto-HSCT was positive in
PBSCs in two cases and negative in 28 cases. One out of
two cases autografted with a positive PCR assessment
relapsed, and only three out of 28 cases (11%) autografted
with negative PCR also relapsed.24 In the patients auto-
grafted with negative PCR, relapse-free survival at 7 years
increased to 87.3%, indicating that auto-HSCT would be
Table 2 Comparison of outocomes from the studies in the autotransplanation for APL
Author
(publication)
N Age
(median)
Disease
status at
transplant
Source
of Auto-
transplant
Pretransplant
BM % PCR
negative
Pretransplant
graft % PCR
negative
% of
TRM
Outocome %DFS/%EFS/
%RFS/%LFS (interval)
median survival median
duration of CR
Mandelli et al.6 187 30 CR1: 129 BM NA NA CR1: 18 CR1: 42±4
(7-year LFS)
CR2: 58 CR2: 23 CR2: 22±8
(4-year LFS)
Meloni et al.26 15 38 CR2: 15 BM 53.3 (8 of 15) NA 0 Median duration of CR
PCR+*: 5 months
PCR**: 28.5 months
Ferrant et al.19 36 NA CR1: 36 BM NA NA NA 70% (3 years LFS)
83% (3 years OS)
Roman et al.21 10 47 CR1: 8 BM 4 100 (2 of 2) NA 0 Median survival: 41 months
CR2: 1 PB 6
PR: 1
Lo Coco et al.25 8 40 CR2: 8 BM 100 (8 of 8) NA 0 Median duration of CR:
11 months
Ottaviani et al.20 16 30 CR1: 13 BM 81.3 (13 of 16) NA 0 Median survival
PR: 1 CR1: 55 months
CR2: 1 CR2: 16 months
CR3: 1
Thomas et al.28 22 NA CR2: 22 BM 5 88.9 (8 of 9) 33.3 (2 of 6) 9 77 (3 years DFS)
PB 17
Ferrara et al.27 6 38 CR2: 6 BM or PB 100 (6 of 6) 100 (6 of 6) 0 Median duration of CR:
36 months
de Botton et al.24 50 45 CR2: 50 BM 43 93.3 (28 of 30) 90.9
(20 of 22)
6 79 (7 years RFS)
PB 7 61 (7 years EFS)
Sanz et al.15 344 50 (CR1) CR1: 149 CR1: BM
92, PB 57
NA NA CR1: 10 CR1: 70 (5 years LFS)
38 (CR2) CR2: 195 CR2: BM
91, PB 104
CR2: 16 CR2: 51 (5 years LFS)
Thirugnanam et al.29 14 33 CR2: 12 PB 100 (14 of 14) NA 0 83±15 (5 years EFS)
CR3: 2
Kamimura et al.
(present study)
26 45 CR1: 20 PB CR1: 100
(15 of 15)
0 CR1: 100 (11 years LFS)
CR2: 6 CR2: 100 (6 of 6) CR2: 100 (3 years LFS)
Abbreviations: CR1¼ first CR; CR2¼ second CR; DFS¼ disease-free survival; LFS¼ leukemia-free survival; NA¼ not available; *PCR+¼pretransplant
BM PCR positive; **PCR¼ pretransplant BM PCR negative.
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effective for the treatment of relapsed APL if performed
in molecular CR2; this was consistent with previous
reports25–27 (Table 2).
Thomas et al.28 reported their experience using ATO as
re-induction therapy for 28 relapsed APL patients. Nine of
24 patients achieving molecular CR underwent auto-
HSCT, and all of them continued in CR2 (2-year LFS
and OS rates of 100%). In our study, six patients had a
relapse of APL after cessation of maintenance therapy,
although all six patients were considered as low-risk
patients; three patients were treated with chemotherapy as
re-induction for relapsed APL before the era of ATO,
whereas the remaining three underwent ATO-containing
chemotherapy. All six patients gained molecular CR2 after
one course of re-induction chemotherapy, and PBSCs were
collected after the subsequent chemotherapy (Table 1). Six
patients received auto-HSCT in CR2, and were continued
in CR without maintenance at a median of 41 months
(2–187 months). Furthermore, Thirugnanam et al.29
recently showed that, following remission induction with
an ATO-based regimen in relapsed APL patients,
consolidation with auto-HSCT was associated with a
significantly superior clinical outcome compared with
ATO-based maintenance; EFS at 5 years was 83.3% in
patients who underwent auto-HSCT vs 34.4% in those who
did not. In addition, as recent evidence has revealed that
ATO treatments comprising at least two cycles can result in
molecular CR in nearly 80% of relapsed APL patients,23
auto-HSCT may become more beneficial for APL patients
in molecular CR2 receiving ATO treatment.
Intensification of pretransplant conditioning by G-CSF
priming may have improved LFS in our study, especially
patients with high risk and in CR2. G-CSF can stimulate
the proliferation of myeloid leukemic cells because most
express receptors for G-CSF, and increase susceptibility of
leukemic cells to cell cycle-specific agent CA. Moreover,
recent evidences have shown that G-CSF can mobilize
hematopoietic stem/progenitor cells from BM niche by
disruption of adhesion molecules such as CXCR4/SDF1
and VCAM1/VLA4.30 In this context, G-CSF can also
mobilize leukemic stem cells into circulation from BM
niche, resulting in the increased susceptibility to chemother-
apeutic agents. Clinical studies support a potential role to
reduce leukemic relapse after HSCT or chemotherapy.10,31–34
Large study will be required to assess further the efficacy of
G-CSF priming for pretransplant conditioning.
Future perspective
Recently, Lee et al.35 reported the importance of serial
measurement of MRD by PCR analysis during therapy in
70 newly diagnosed APL patients. According to their
prospective study, MRD after upfront ATRA and anthra-
cycline-based induction chemotherapy was detectable in
half of the patients and was undetectable in the remaining
half. All patients negative for PCR after induction had
a favorable clinical course thereafter, without relapse.
In contrast, after the first consolidation, MRD was still
detectable exclusively in about 30% of the patients positive
for PCR after induction, who were highly susceptible
to subsequent hematologic relapses, despite additional
consolidation.35 Therefore, patients who remain PCR
positive after the first consolidation may be candidates
requiring further ATO-containing treatment followed by
HSCT: auto-HSCT has a strong anti-APL activity and
potent roles in the treatment of APL, particularly in
molecular CR, whereas allogeneic HSCT would be
recommended for patients who fail to gain molecular CR.
Large prospective studies and careful follow-ups with serial
quantification of MRD would be needed to assess the value
of an individualized, response-oriented treatment strategy
and the role of HSCT in the treatment of APL patients.
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